<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04445857</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 6379</org_study_id>
    <nct_id>NCT04445857</nct_id>
  </id_info>
  <brief_title>Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine on Spinal Anesthesia in Tramadol-abuse Patients</brief_title>
  <official_title>Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine on Spinal Anesthesia in Lower Abdominal and Limb Surgeries in Tramadol-abuse Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing duration of local anesthetic action is desired for prolongation of postoperative
      patient comfort, as well as decreasing perioperative opioid consumption and subsequent side
      effects. Calcitonin, discovered in 1961, has been established, synthesized, and developed for
      use in treating disease. In 1983 it was demonstrated that calcitonin is an analgesic, which
      is also effective in the epidural and subarachnoid spaces.Tramadol abuse has dramatically
      increased in Egypt since 2008 and has led to many admissions to addiction treatment
      centers.It was shown that the duration of sensory block of spinal anesthesia with hyperbaric
      bupivacaine in chronic opium abusers undergoing lower extremity orthopedic surgery was much
      shorter in chronic opium abusers compared with non-abusers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The length of the sensory block (min) of spinal anesthesia in tramadol-abuse patients intrathecally or i.v.</measure>
    <time_frame>procedure</time_frame>
    <description>The length of the sensory block (min) of spinal anesthesia in tramadol-abuse patients intrathecally or i.v.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 100 IU salmon calcitonin(1ml) intrathecally and injection of 10 ml normal saline (NS) slowly intravenously (IV) over 5 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 100 IU salmon calcitonin (1ml) diluted in 9 ml NS slowly IV over 5 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (control group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>injection of 15 mg (2.5 ml) hyperbaric bupivacaine 0.5% and 1ml NS intrathecally and injection of 10 ml NS slowly IV over 5 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin presented as MiacalcicÂ® ampoules 100 IU/ml (1ml)</intervention_name>
    <description>coadministration of calcitonin and a single-shot hyperbaric bupivacaine prolongs the length of the sensory block (min) of SA in tramadol-abuse patients independent of the route of calcitonin administration intrathecally or i.v.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline (NS)</intervention_name>
    <description>1ml NS intrathecally OR injection of 10 ml NS slowly IV over 5 min.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3 (control group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with history of substance use disorders (SUD) history of tramadol addiction
             (single drug addiction and substances used besides tramadol) and duration of addiction
             &gt;1 year

          -  Elective lower abdomen or lower extremities surgeries under spinal anesthesia

          -  ASA physical status I and II

        Exclusion Criteria:

          -  Patient`s refusal,

          -  duration of surgery more than 120 min,

          -  obesity with body mass index (BMI) &gt;35 kg/m2,

          -  generalized infection or localized infection at level of blockade,

          -  neurological disease,

          -  psychological disorder

          -  coagulation disorder,

          -  history of uncontrolled hypertension,

          -  history of uncontrolled blood sugar,

          -  allergy to bupivacaine or calcitonin

          -  or failed spinal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ibrahim Mamdouh Esmat, MD</last_name>
    <phone>01001241928</phone>
    <email>ibrahim_mamdouh@med.asu.edu.eg</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 21, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr.Ibrahim Mamdouh Esmat</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Katacalcin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

